A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer
1. Primary Purpose: response rate
2. Secondary purpose: toxicity, progression-free survival, overall survival